Healthcare
Live Price
Offline$48.32
-1.59% today
Window Change
-8.57%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sonova Holding AG (SONVY) is a Healthcare stock with a market cap of $10.21B and listed on OTC. The stock last traded around $48.32 and down 8.6% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of +6.6%, EPS growth of -9.8%, a dividend yield of 2.6%. What stands out right now is revenue +6.6%, EPS -9.8%, free cash flow +5.0% with operating margin 18.2% and ROIC 12.6%. The dividend matters to the case here, with a current yield around 2.6%. Valuation is more restrained than many high-expectation growth names at P/E 19.6 and price/sales 2.7. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SONVY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SONVY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SONVY Max Drawdown
-8.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SONVY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.6B
-22.7% YoY
FY Net Income
$581.0M
-10.5% YoY
Free Cash Flow
$665.5M
-18.4% YoY
Revenue Growth
+6.6%
EPS Growth
-9.8%
Gross Margin
70.5%
Net Margin
13.5%
Income statement
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.9B | 3.6B | 3.7B | 3.4B | 2.6B |
| Gross Profit | 2.8B | 2.6B | 2.6B | 2.4B | 1.8B |
| Operating Income | 692M | 670M | 762M | 785M | 559M |
| EBITDA | 927M | 922M | 979M | 961M | 755M |
| Net Income | 541M | 601M | 648M | 649M | 581M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CHF
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 687M | 514M | 414M | 611M | 1.8B |
| Total Assets | 5.9B | 5.8B | 5.6B | 5.6B | 5.9B |
| Total Liabilities | 3.2B | 3.3B | 3.3B | 3.2B | 3.2B |
| Shareholder Equity | 2.7B | 2.5B | 2.2B | 2.4B | 2.7B |
| Total Debt | 1.8B | 1.8B | 1.8B | 1.5B | 1.8B |
| Net Debt | 1.1B | 1.3B | 1.4B | 874M | 62M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
755M
-18.2% YoY
Capital Expenditures
89M
+16.3% YoY
Free Cash Flow
666M
-18.4% YoY
Key ratios
Gross Margin
70.5%
Operating Margin
18.2%
Net Margin
13.5%
ROE
20.4%
Debt / Equity
0.76x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.